10x Genomics (TXG) Accumulated Expenses (2018 - 2026)

10x Genomics has disclosed Accumulated Expenses across 9 years of filings, most recently posting $21.5 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $21.5 million, down 52.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (down 52.72% YoY), and the FY2025 annual result was $42.5 million, up 3.24% from the prior year.
• Accumulated Expenses came in at $21.5 million for Q1 2026 at 10x Genomics, down from $42.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $62.0 million in Q3 2022 to a low of $20.7 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $39.1 million (2025), against an average of $37.9 million.
• Across the five-year window, Accumulated Expenses plunged 56.38% in 2024 and soared 120.04% in 2025, its largest moves.
• 10x Genomics' Accumulated Expenses stood at $59.8 million in 2022, then tumbled by 49.64% to $30.1 million in 2023, then surged by 36.74% to $41.2 million in 2024, then advanced by 3.24% to $42.5 million in 2025, then slumped by 49.4% to $21.5 million in 2026.
• The last three Accumulated Expenses figures came in at $21.5 million (Q1 2026), $42.5 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.